Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

[Image: see text] The imidazolyl-tetrahydro-β-carboline class of sstr3 antagonists have demonstrated efficacy in a murine model of glucose excursion and may have potential as a treatment for type 2 diabetes. The first candidate in this class caused unacceptable QTc interval prolongation in oral, tel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:ACS Med Chem Lett
Autores principales: Shah, Shrenik K., He, Shuwen, Guo, Liangqin, Truong, Quang, Qi, Hongbo, Du, Wu, Lai, Zhong, Liu, Jian, Jian, Tianying, Hong, Qingmei, Dobbelaar, Peter, Ye, Zhixiong, Sherer, Edward, Feng, Zhe, Yu, Yang, Wong, Frederick, Samuel, Koppara, Madiera, Maria, Karanam, Bindhu V., Reddy, Vijay B., Mitelman, Stan, Tong, Sharon X., Chicchi, Gary G., Tsao, Kwei-Lan, Trusca, Dorina, Feng, Yue, Wu, Margaret, Shao, Qing, Trujillo, Maria E., Eiermann, George J., Li, Cai, Pachanski, Michele, Fernandez, Guillermo, Nelson, Donald, Bunting, Patricia, Morissette, Pierre, Volksdorf, Sylvia, Kerr, Janet, Zhang, Bei B., Howard, Andrew D., Zhou, Yun-Ping, Pasternak, Alexander, Nargund, Ravi P., Hagmann, William K.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Chemical Society 2015
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434471/
https://ncbi.nlm.nih.gov/pubmed/26005524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml500514w
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares